3 Things the Smartest Investors Know About This Beaten-Down Stock
fool.com
news
2022-10-20 10:00:00

Most people consider Moderna (MRNA -7.88%) a coronavirus vaccine stock. And for good reason. The vaccine is the company's only product right now. And it's generated billions of dollars in revenue and profit for this biotech player.
Moderna's status as a vaccine stock once brought it major gains. But today, just the opposite is happening. Some investors have dropped Moderna and moved on to other investment themes. But the Moderna story is far from over. And some pretty exciting chapters may lie ahead.
